Flagship-backed ‘gene-writing’ startup Tessera raises $300M

Little more than a year after it raised a $230 million Series B round, Flagship Pioneering spinout Tessera Therapeutics has raised $300 million in a Series C round that it intends to funnel into a massive hiring push and a manufacturing buildout.